Original site: www.cdc.gov/mmwr/preview/mmwrhtml/mm5705a5.htm RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Guidance for Presentation of Economic Studies to
the Advisory Committee on Immunization Practices
The charter of the Advisory Committee on Immunization Practices (ACIP) states that committee deliberations on
the appropriate use of vaccines should include consideration of population-based studies such as efficacy,
cost-benefit, and risk-benefit analyses (1). As the number and cost of vaccines have increased, economic analyses have
become an essential aspect of the development of policy recommendations for their use. To ensure that economic data presented to the
ACIP and its working groups are of the highest scientific quality, readily understandable, and uniform in presentation,
CDC economists have developed Guidance for Health Economics Studies Presented to the ACIP. This guidance, approved
by ACIP on June 27, 2007, mandates formal technical review of any economic study before its presentation to the
ACIP, effective as of the ACIP meeting, June 25--26, 2008.
The Guidance requires that all economic data presented to the ACIP be reviewed by anonymous peer reviewers
within CDC. When a reviewer with a particular area of economic expertise is not available within CDC, external reviewers
may be used. Materials to be submitted for review must include a report that provides the methods and results of the
study, slides, and other presentation materials as needed. The report and other materials must be sent to the appropriate
ACIP working group no later than 8 weeks before the ACIP general meeting or working group meeting at which the analysis
is scheduled to be presented. Reviewers will consult with relevant CDC subject-matter experts and return comments
and questions in writing to the National Center for Immunization and Respiratory Diseases lead economist (or designee)
at least 4 weeks in advance of the formal presentation. Additional details are included in the guidance document, which
is available at
http://www.cdc.gov/vaccines/recs/acip/economic-studies.htm.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
